FACTOR X
( DrugBank: Factor X / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 288 | 自己免疫性後天性凝固因子欠乏症 | 35 |
288. 自己免疫性後天性凝固因子欠乏症
臨床試験数 : 206 / 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21
Showing 1 to 10 of 35 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03161626 (ClinicalTrials.gov) | February 27, 201820180227 | 18/5/201720170518 | Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor XDeficiency Undergoin ... | A Multicenter, Post-Marketing Registry Study of COAGADEX® in the Peri-operative Management of Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery A Multicenter, Post-Marketing Registry Study of COAGADEX® in the Peri-operative Management of Patien ... | Factor 10 Deficiency | Drug: Coagadex | Bio Products Laboratory | NULL | Completed | 12 Years | N/A | All | 3 | United States | |
| 2 | NCT01721681 (ClinicalTrials.gov) | April 201520150400 | 25/10/201220121025 | A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor Xin the Prophylaxis of Bleeding in ... | A Phase III Open, Multicentre Study to Investigate the Safety, Pharmacokinetics and Efficacy of BPL's High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years A Phase III Open, Multicentre Study to Investigate the Safety, Pharmacokinetics and Efficacy of BPL' ... | Factor X Deficiency | Biological: FACTOR X | Bio Products Laboratory | NULL | Completed | N/A | 11 Years | All | 9 | Phase 3 | United Kingdom |
| 3 | EUCTR2012-003093-98-GB (EUCTR) | 24/02/201520150224 | 02/01/201320130102 | The purpose of this study is to look at how well FACTOR X works in preventing bleeding when taken regularly in children aged under 12 years old, over a period of 6 months. The study will also look at how safe FACTOR X is by closely following the subjects progress during the study. The purpose of this study is to look at how well FACTOR Xworks in preventing bleeding when taken reg ... | A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s Hi ... | Factor X Deficiency;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Human factor X Product Code: FACTOR X INN or Proposed INN: Human Coagulation Factor X Other descriptive name: FACTOR X Product Name: Human factor X Product Code: FACTOR X INN or Proposed INN: Human Coagulation Factor X Oth ... | Bio Products Laboratory Limited | NULL | Not Recruiting | Female: yes Male: yes | 8 | Phase 3 | Turkey;United Kingdom | ||
| 4 | EUCTR2009-015086-31-ES (EUCTR) | 03/05/201220120503 | 27/02/201220120227 | A study for people with coagulation factor X deficiency, to assess the effectiveness and safety of a high purity factor X concentrate for people having surgery. A study for people with coagulation factor Xdeficiency, to assess the effectiveness and safety of a ... | Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Puri ... | Factor X Deficiency;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Human factor X Product Code: FACTOR X Other descriptive name: FACTOR X | Bio Products Laboratory Limited | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 3 | United States;Spain;Turkey;Germany;United Kingdom;India | ||
| 5 | NCT01086852 (ClinicalTrials.gov) | March 201120110300 | 10/11/200920091110 | Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery Safety & Efficacy of BPL's High Purity FACTOR Xin Treatment of Factor XDeficient Subjects Undergoing ... | A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL's High Purity FACTOR X in the Treatment of Factor X Deficient Subjects Undergoing Surgery A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL's High Purity FACT ... | Factor X Deficiency | Biological: FACTOR X | Bio Products Laboratory | NULL | Terminated | 12 Years | N/A | All | 4 | Phase 3 | United States;Spain;Turkey;United Kingdom;Germany |
| 6 | EUCTR2009-011145-18-DE (EUCTR) | 21/09/201020100921 | 01/04/201020100401 | A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency - A PK study of BPL's FX in patients with FX deficiency A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL' ... | A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency - A PK study of BPL's FX in patients with FX deficiency A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL' ... | Factor X deficiency MedDRA version: 12.1;Level: LLT;Classification code 10052474;Term: Factor X deficiency Factor Xdeficiency MedDRA version: 12.1;Level: LLT;Classification code 10052474;Term: Factor Xdefici ... | Product Name: Human factor X Product Code: FACTOR X Other descriptive name: Human factor X | Bio Products Laboratory Limited | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 3 | Spain;Germany;United Kingdom | ||
| 7 | EUCTR2009-016869-28-GB (EUCTR) | 20/09/201020100920 | 07/07/201020100707 | A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Deficiency A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose ... | A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Deficiency A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose ... | Congenital FXIII A-subunit Deficiency MedDRA version: 13.1;Level: PT;Classification code 10016083;Term: Factor XIII deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders Congenital FXIII A-subunit Deficiency MedDRA version: 13.1;Level: PT;Classification code 10016083;Te ... | Product Name: Recombinant factor XIII (rFXIII) Product Code: NN 1841 INN or Proposed INN: Catridecacog Other descriptive name: Recombinant factor XIII (rFXIII) Product Name: Recombinant factor XIII (rFXIII) Product Code: NN 1841 INN or Proposed INN: Catridecacog ... | Novo Nordisk A/S | NULL | Not Recruiting | Female: yes Male: yes | 6 | Phase 3 | United Kingdom | ||
| 8 | EUCTR2010-020192-23-GB (EUCTR) | 20/09/201020100920 | 06/08/201020100806 | A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Paediatric Subjects with Congenital Factor XIII A-subunit Deficiency Safety Extension Trial to F13CD-3760 A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Effica ... | A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Paediatric Subjects with Congenital Factor XIII A-subunit Deficiency Safety Extension Trial to F13CD-3760 A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Effica ... | Congenital Factor XIII A-subunit Deficiency MedDRA version: 17.0;Level: PT;Classification code 10016083;Term: Factor XIII deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders Congenital Factor XIII A-subunit Deficiency MedDRA version: 17.0;Level: PT;Classification code 10016 ... | Product Name: Recombinant factor XIII (rFXIII) Product Code: NN1841 INN or Proposed INN: Catridecacog Other descriptive name: Recombinant factor XIII (rFXIII) Product Name: Recombinant factor XIII (rFXIII) Product Code: NN1841 INN or Proposed INN: Catridecacog O ... | Novo Nordisk A/S | NULL | Not Recruiting | Female: yes Male: yes | 6 | France;Finland;Spain;Denmark;Austria;Germany;Italy;United Kingdom;Sweden | |||
| 9 | EUCTR2009-015086-31-GB (EUCTR) | 16/03/201020100316 | 17/03/201020100317 | A study for people with coagulation factor X deficiency, to assess the effectiveness and safety of a high purity factor X concentrate for people having surgery. A study for people with coagulation factor Xdeficiency, to assess the effectiveness and safety of a ... | Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Puri ... | Factor X Deficiency;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Human factor X Product Code: FACTOR X Other descriptive name: FACTOR X | Bio Products Laboratory Limited | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 3 | United States;Spain;Turkey;Germany;United Kingdom;India | ||
| 10 | EUCTR2008-007883-41-AT (EUCTR) | 15/03/201020100315 | 25/01/201020100125 | A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) inSubjects with Congenital Factor XIII Deficiency(Safety Extension Trial to F13CD-1725) A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement T ... | A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) inSubjects with Congenital Factor XIII Deficiency(Safety Extension Trial to F13CD-1725) A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement T ... | Congenital Factor XIII Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10010432;Term: Congenital deficiency of other clotting factors MedDRA version: 9.1;Classification code 10061992;Term: Haemophilia MedDRA version: 9.1;Level: HLT;Classification code 10009735;Term: Coagulation disorders congenital Congenital Factor XIII Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10010432;Term: ... | Product Name: Recombinant factor XIII (rFXIII) INN or Proposed INN: Catridecacog Other descriptive name: Recombinant factor XIII (rFXIII) Product Name: Recombinant factor XIII (rFXIII) INN or Proposed INN: Catridecacog Other descriptive nam ... | Novo Nordisk A/S | NULL | Not Recruiting | Female: yes Male: yes | 40 | France;Finland;Spain;Austria;Germany;Italy;United Kingdom |